Literature DB >> 28197370

Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma.

Yuki Honda1, Atsushi Otsuka1, Sachiko Ono1, Yosuke Yamamoto1, Judith A Seidel1, Satoshi Morita2, Masahiro Hirata3, Tatsuki R Kataoka3, Tatsuya Takenouchi4, Kazuyasu Fujii5, Takuro Kanekura5, Yuko Okubo6, Kenzo Takahashi6, Teruki Yanagi7, Daichi Hoshina7, Hiroo Hata7, Riichiro Abe8, Taku Fujimura9, Takeru Funakoshi9, Koji Yoshino10, Mamiko Masuzawa11, Yasuyuki Amoh12, Ryota Tanaka12, Yasuhiro Fujisawa13, Tetsuya Honda1, Kenji Kabashima1.   

Abstract

Cutaneous angiosarcoma (CAS) is a malignant sarcoma with poor prognosis. Programmed cell death-1 (PD-1)/programmed cell death-1 ligand-1 (PD-L1) expression reflects antitumor immunity, and is associated with patient prognosis in various cancers. The purpose of this study is to investigate the relationship between PD-1/PD-L1 expression and CAS prognosis. CAS cases (n = 106) were immunohistochemically studied for PD-L1 and PD-1 expression, and the correlation with patient prognosis was analyzed. PD-L1 expression was assessed by flow cytometry on three CAS cell lines with or without IFNγ stimulation. A total of 30.2% of patients' samples were positive for PD-L1, and 17.9% showed a high infiltration of PD-1-positive cells. Univariate analysis showed a significant relationship between a high infiltration of PD-1-positive cells with tumor site PD-L1 expression and favorable survival in stage 1 patients (p = 0.014, log-rank test). Multivariable Cox-proportional hazard regression analysis also showed that patients with a high infiltration of PD-1-positive cells with tumor site PD-L1 expression were more likely to have favorable survival, after adjustment with possible confounders (hazard ratio (HR) = 0.38, p = 0.021, 95% confidence interval (CI) 0.16-0.86). Immunofluorescence staining of CAS samples revealed that PD-L1-positive cells were adjacent to PD-1-positive cells and/or tumor stroma with high IFNγ expression. In vitro stimulation with IFNγ increased PD-L1 expression in two out of three established CAS cell lines. Our results suggest that PD-1/PD-L1 expression is related to CAS progression, and the treatment with anti-PD-1 antibodies could be a new therapeutic option for CAS.

Entities:  

Keywords:  Cutaneous angiosarcoma; IFNγ; PD-1; PD-L1; T cells

Year:  2016        PMID: 28197370      PMCID: PMC5283640          DOI: 10.1080/2162402X.2016.1253657

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  35 in total

1.  Cutaneous angiosarcoma: own experience over 13 years. Clinical features, disease course and immunohistochemical profile.

Authors:  D Donghi; K Kerl; R Dummer; N Schoenewolf; A Cozzio
Journal:  J Eur Acad Dermatol Venereol       Date:  2010-10       Impact factor: 6.166

2.  A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy.

Authors:  Matthew G Fury; Cristina R Antonescu; Kimberly J Van Zee; Murray F Brennan; Robert G Maki
Journal:  Cancer J       Date:  2005 May-Jun       Impact factor: 3.360

3.  Establishment of a new murine-phenotypic angiosarcoma cell line (ISOS-1).

Authors:  M Masuzawa; T Fujimura; M Tsubokawa; S Nishiyama; K Katsuoka; E Terada; S Kunita; Y Sakurai; H Kato
Journal:  J Dermatol Sci       Date:  1998-01       Impact factor: 4.563

4.  Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells.

Authors:  Michael J Eppihimer; Jason Gunn; Gordon J Freeman; Edward A Greenfield; Tetyana Chernova; Jamie Erickson; John P Leonard
Journal:  Microcirculation       Date:  2002-04       Impact factor: 2.628

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  Cutaneous angiosarcoma of the head and neck.

Authors:  D J Hodgkinson; E H Soule; J E Woods
Journal:  Cancer       Date:  1979-09       Impact factor: 6.860

7.  Prognosis of lymph node metastasis in soft tissue sarcoma.

Authors:  Kasim A Behranwala; Roger A'Hern; Al-Muderis Omar; J Meirion Thomas
Journal:  Ann Surg Oncol       Date:  2004-07       Impact factor: 5.344

8.  PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status.

Authors:  Delphine Sauce; Jorge R Almeida; Martin Larsen; Laurine Haro; Brigitte Autran; Gordon J Freeman; Victor Appay
Journal:  AIDS       Date:  2007-10-01       Impact factor: 4.177

9.  PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.

Authors:  Cécile Badoual; Stéphane Hans; Nathalie Merillon; Cordélia Van Ryswick; Patrice Ravel; Nadine Benhamouda; Emeline Levionnois; Mevyn Nizard; Ali Si-Mohamed; Nicolas Besnier; Alain Gey; Rinat Rotem-Yehudar; Hélène Pere; Thi Tran; Coralie L Guerin; Anne Chauvat; Estelle Dransart; Cécile Alanio; Sebastien Albert; Beatrix Barry; Federico Sandoval; Françoise Quintin-Colonna; Patrick Bruneval; Wolf H Fridman; Francois M Lemoine; Stephane Oudard; Ludger Johannes; Daniel Olive; Daniel Brasnu; Eric Tartour
Journal:  Cancer Res       Date:  2012-11-07       Impact factor: 12.701

10.  CD8⁺ tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma.

Authors:  Hiroko Fujii; Akiko Arakawa; Daisuke Utsumi; Shinji Sumiyoshi; Yosuke Yamamoto; Akihiko Kitoh; Masahiro Ono; Yumi Matsumura; Mayumi Kato; Keisuke Konishi; Takeo Shiga; Shigetoshi Sano; Shimon Sakaguchi; Aya Miyagawa-Hayashino; Kenzo Takahashi; Hiroshi Uezato; Yoshiki Miyachi; Miki Tanioka
Journal:  Int J Cancer       Date:  2013-11-18       Impact factor: 7.396

View more
  22 in total

Review 1.  Angiosarcomas: histology, immunohistochemistry and molecular insights with implications for differential diagnosis.

Authors:  Isidro Machado; Francisco Giner; Javier Lavernia; Julia Cruz; Víctor Traves; Celia Requena; Beatriz Llombart; José Antonio López-Guerrero; Antonio Llombart-Bosch
Journal:  Histol Histopathol       Date:  2020-09-04       Impact factor: 2.303

2.  A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas.

Authors:  Thomas G P Grünewald; Thomas Knösel; Martin F Orth; Veit Leonhard Buecklein; Eric Kampmann; Marion Subklewe; Elfriede Noessner; Florencia Cidre-Aranaz; Laura Romero-Pérez; Fabienne Sophie Wehweck; Lars Lindner; Rolf Issels; Thomas Kirchner; Annelore Altendorf-Hofmann
Journal:  Cancer Immunol Immunother       Date:  2020-03-28       Impact factor: 6.968

3.  A novel humanized anti-PD-1 monoclonal antibody potentiates therapy in oral squamous cell carcinoma.

Authors:  Y Cai; Fei Wang; Q Liu; Z Li; D Li; Z Sun
Journal:  Invest New Drugs       Date:  2018-10-27       Impact factor: 3.850

4.  Integrated analysis of programmed cell death ligand 1 expression reveals increased levels in high-grade glioma.

Authors:  Dorothee Hölzl; Georg Hutarew; Barbara Zellinger; Hans U Schlicker; Christoph Schwartz; Peter A Winkler; Karl Sotlar; Theo F J Kraus
Journal:  J Cancer Res Clin Oncol       Date:  2021-05-08       Impact factor: 4.553

5.  Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis.

Authors:  Zhenhua Zhu; Zheng Jin; Mei Zhang; Yajun Tang; Guang Yang; Xiaowei Yuan; Jihang Yao; Dahui Sun
Journal:  Oncotarget       Date:  2017-07-11

Review 6.  Cutaneous Angiosarcoma: The Possibility of New Treatment Options Especially for Patients with Large Primary Tumor.

Authors:  Yasuhiro Fujisawa; Koji Yoshino; Taku Fujimura; Yoshiyuki Nakamura; Naoko Okiyama; Yosuke Ishitsuka; Rei Watanabe; Manabu Fujimoto
Journal:  Front Oncol       Date:  2018-03-02       Impact factor: 6.244

Review 7.  Cutaneous angiosarcoma: update on biology and latest treatment.

Authors:  Yoshihiro Ishida; Atsushi Otsuka; Kenji Kabashima
Journal:  Curr Opin Oncol       Date:  2018-03       Impact factor: 3.645

Review 8.  Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.

Authors:  Judith A Seidel; Atsushi Otsuka; Kenji Kabashima
Journal:  Front Oncol       Date:  2018-03-28       Impact factor: 6.244

9.  PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer.

Authors:  Yanhua Wu; Donghui Cao; Limei Qu; Xueyuan Cao; Zhifang Jia; Tiancheng Zhao; Quan Wang; Jing Jiang
Journal:  Oncotarget       Date:  2017-07-18

10.  Prognostic implications of PD-L1 expression in patients with angiosarcoma.

Authors:  Jii Bum Lee; Beung-Chul Ahn; Seung Hyun Kim; Young Han Lee; Jung Woo Han; Min Kyung Jeon; Soo Hee Kim; Hyo Song Kim
Journal:  Future Sci OA       Date:  2021-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.